NurExone Biologic Inc. V.NRX

NurExone May Hold The Key To Potential Breakthrough In Acute

[RealREIT$]

An estimated 250,000-500,000 people experience a Spinal Cord Injury (SCI) annually, with roughly 17,000 new cases in the US and 27,000 in Europe each year, leaving many of those people permanently confined to a wheelchair. What if there were a way to repair the damaged tissue and allow those people to once again have feeling and regain use of their limbs? Thanks to tiny particles known as exosomes, such a miracle may be on the horizon.
 
Exosomes are small extracellular vesicles that are secreted by all Stem Cell types. They are thought to play a role in cell-to-cell communication.
 
Exosomes contain a variety of proteins, lipids, and nucleic acids, and have diverse potential in emerging technologies to address areas of unmet medical need. Exosomes can be used to deliver drugs, genes, and other molecules to target cells, making them ideal for new therapeutics and improving existing drugs. Plus, they also can function as potential biomarkers, giving them unique value in diagnostics applications. It’s not hyperbole that exosomes may revolutionize many standards of care and provide people hope in diseases fraught with desperation.
 
Every year, thousands of people are relegated to wheelchairs because of irreparable spinal cord injuries. Research suggests that exosomes can be used to regenerate damaged tissue and organs.
 
Further, in addition to being used to deliver drugs to diseased cells, exosomes have also been shown to be effective in reducing inflammation and stimulating the immune system. To wit, it should be unsurprising that exosomes are a rapidly growing field of research.
 
The buzz around exosomes and their ability to carry payloads from one cell to another has been steadily growing, evidenced by Bio-Techne Corporation (NASDAQ: TECH) in 2018 agreeing to pay $250 million in cash (and up to $325 million for achieving certain milestones) to acquire Exosome Diagnostics. In 2020, Eli Lilly (NYSE: LLY) made a $20 million upfront payment to launch a deal that could be worth up to $1.2 billion for Evox Therapeutics pursuant to which Evox agreed to provide DeliverEX™, its exosome-based drug delivery platform, to allow targeted drug delivery across the blood-brain barrier. Others that have compelling exosome technology in development include Capricor Therapeutics, Inc. (NASDAQ: CAPR) and NurExone Biologic Inc. (TSX-Venture: NRX).
 
Capricor’s StealthX™ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted therapies to treat or prevent a variety of diseases.
 
NurExone Biologic Inc. (TSX-Venture: NRX) has assembled an expert team in its mission to revolutionize recovery from nervous system injuries by regenerating and rewiring neurons. The Israel-based company is at the forefront of exosome-based therapeutics R&D, developing and commercializing exosome-based therapies and a production platform for a global market projected at $5.2 billion.
 
With operations launched in 2020, NurExone possesses a lot more fundamental strength than is typically found in such a young company. The company obtained an exclusive worldwide license from the Technion and Tel Aviv University to develop and commercialize an exosome technology that has been under development for 10+ years. NurExone has a global vision and has submitted patent applications in the U.S. and other key markets under the Patent Cooperation Treaty (PCT), with a first U.S. patent awarded in January. The rest of the IP portfolio includes 2 PCTs on Production and Composition of Matter of its exosomes and 4 provisional patents on loading technique and siRNA target sequences.
 
NurExone operates according to two business lines – Development of a first exosome-based therapy for acute SCI (spinal cord injuries). In parallel, the company plans to soon monetize its proprietary exosome technology and production platform through licensing to the global biopharmaceutical industry for other diseases and indications.